Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Discuss Creation of Post-Launch Premium for Add’l Indications: Official
March 20, 2018
- MHLW Health Policy Chief Questions Volume-Focused Sales Strategies, Urges Drug Makers to Shift to Healthy Lifespan Extension
March 19, 2018
- Lift Ban on Coadministration of Adrenalin Medications with Alpha-blocking Antipsychotic Drugs: MHLW Panel
March 19, 2018
- PMDA Estimates MID-NET Will Be Used for PMS for 18 Products Annually
March 16, 2018
- 3rd Batch of Sakigake Drugs to Be Announced Soon: MHLW Official
March 15, 2018
- MHLW Issues Safety Information with Special Feature on MID-NET Expected to Begin Full-Scale Operation on April 1
March 15, 2018
- PMDA’s Review Segment to Post Loss of around 500 Million Yen in FY2017; Ordinary Loss to Be Covered by Reserve Fund
March 14, 2018
- PMDA to Establish “Regulatory Science Center” in April to Deal with Advanced Science and Technology
March 14, 2018
- MHLW to Relax Regulatory Procedures to Prevent Discrepancies between Approved and Actual Manufacturing Practices
March 13, 2018
- Lexicon: G1/G2 Rule
March 9, 2018
- AMED Taking Applications for FY2018 CiCLE Grant Program, Will Make Final Selection by Early October
March 9, 2018
- Funding Disclosure Methods that Prohibit Printing Will Not Be Acceptable: MHLW Notifications on Clinical Research Law
March 9, 2018
- MHLW Proposes Working Group Discussions before Another Round of CEA Analyses for 7 Products: Chuikyo
March 8, 2018
- Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
March 8, 2018
- Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
March 8, 2018
- Why Did Xarelto, Eliquis Lose PMP Eligibility?
March 7, 2018
- Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
March 7, 2018
- 10 Billion Yen Could Be Saved If 80% Gx Use Achieved among Welfare Recipients: Govt
March 6, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…